e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Lung cancer biology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma
M. Petrovic, Z. Lazic, I. Cekerevac, L. Novkovic, V. Cupurdija (Kragujevac, Republic Of Serbia)
Source:
Annual Congress 2009 - Lung cancer biology
Session:
Lung cancer biology
Session type:
E-Communication Session
Number:
299
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Petrovic, Z. Lazic, I. Cekerevac, L. Novkovic, V. Cupurdija (Kragujevac, Republic Of Serbia). p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma. Eur Respir J 2009; 34: Suppl. 53, 299
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer
Source: Annual Congress 2007 - Novel genetic markers in pathology
Year: 2007
Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 230s
Year: 2001
Management of EGFR mutated nonsmall cell lung carcinoma patients
Source: Eur Respir J 2015; 45: 1132-1141
Year: 2015
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
K-RAS oncogenic mutations in patients with nonsmall cell lung cancer
Source: Annual Congress 2007 - Biology of thoracic malignancies
Year: 2007
A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006
MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002
An analysis of EGFR expression and tumour imaging in non-small cell carcinomas of lung
Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients
Year: 2011
XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Deguelin enhances chemosensitivity of non-small cell lung cancer cells
Source: Eur Respir J 2006; 28: Suppl. 50, 336s
Year: 2006
TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
Does long treatment delay affect survival in metastatic non-small cell lung cancer
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance
Source: Eur Respir J 2001; 18: Suppl. 33, 230s
Year: 2001
The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer
Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology
Year: 2019
Proliferative activity of non-small cell lung cancer after induction chemotherapy
Source: Eur Respir J 2005; 26: Suppl. 49, 328s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept